Precision Begins at
the Epigenome
28M+
CpG Sites
400+
Histone Marks
100%
Patient-Centered
Board
Certified Standard
Ep·i·ge·nom·ics
/ ˌepəjəˈnōmiks / · noun
noun · precision scienceThe study of heritable changes in gene expression that do not involve alterations to the underlying DNA sequence including DNA methylation, histone modification, and chromatin remodeling - and their role in health and disease.
Origin
From Greek epi- (upon, above) + genesis (origin) + -ome (complete set). The concept was introduced by Conrad Waddington in 1942 to describe how genes interact with their environment to produce a phenotype.
The Epigenomics Department at the American Board of Precision Medicine explores the layer of biological regulation that sits above the genome itself - training clinicians to understand how environmental exposures, lifestyle factors, and aging rewrite the chemical marks that govern gene expression without changing a single base pair.
From DNA methylation profiling and histone modification mapping to chromatin accessibility assays and non-coding RNA analysis, this department equips physicians to interpret epigenetic signatures that drive cancer, cardiovascular disease, neurological conditions, and aging, and to apply that knowledge at the point of care.
Unlike the fixed sequence of the genome, the epigenome is dynamic and potentially reversible making it one of the most promising frontiers for therapeutic intervention and at ABOPM, a cornerstone of precision medicine training.
28M+
CpG Sites
400+
Histone Marks
∞
Clinical Possibilities
Where the Epigenome Meets
Clinical Purpose
The Epigenomics Department at ABOPM exists at the intersection of gene regulation science and patient care - training physicians to decode the epigenome, apply its insights, and transform outcomes across every clinical specialty.
Advancing research in DNA methylation, histone modification, chromatin remodeling, and non-coding RNA regulation expanding our understanding of how gene expression shapes human health and disease without altering the underlying sequence.
Bridging epigenetic laboratory science and bedside medicine - developing board-certified frameworks for epigenetic biomarker interpretation, reversible disease modification, and precision therapeutic targeting across oncology, aging, and metabolic medicine.
Building the next generation of epigenomics-fluent clinicians through rigorous board standards, interdisciplinary training, and collaboration across molecular biology, oncology, neurology, and environmental medicine.
"The epigenome is not written in stone - it is written in experience. The Epigenomics Department at ABOPM trains physicians to read those marks, interpret their clinical signals, and intervene with precision and purpose."
American Board of Precision Medicine · Epigenomics DepartmentTranslating the Epigenome
Into Clinical Impact
The epigenome is the most clinically actionable layer of human biology - written not in sequence, but in experience. Learning to read it is not optional for the future of medicine - it is foundational.
Epigenomics equips clinicians to move beyond static genetic risk and into the dynamic, reversible mechanisms that regulate gene expression - enabling earlier detection, targeted intervention, and care that responds to environment, behavior, and disease at the molecular level.
By mastering epigenomics, clinicians gain the power to:
Why Epigenomics Fluency Is Non-Negotiable
The regulatory layer is here. The clinical tools are ready. The question is, are you?
Epigenomics-guided care opens therapeutic windows unavailable to genomics alone - targeting reversible marks to restore normal gene expression and halt disease progression.
Epigenetic drugs are already FDA-approved across oncology, and methylation-based diagnostics are entering routine clinical use - clinicians who can't interpret them will be left behind.
Board certification in epigenomics positions you as a recognized leader at the intersection of molecular biology and clinical medicine where few physicians currently hold expertise.
Epigenomics spans every specialty: oncology, neurology, immunology, aging medicine, and reproductive health giving you tools that connect biology, environment, and disease across all of medicine.
Active research areas driving epigenomic medicine forward:
The epigenomics revolution is not a future event - it is happening now. DNA methylation clocks, histone-targeting therapies, and chromatin-level biomarkers are actively reshaping how disease is understood, detected, and treated at the gene regulation level.
The ABOPM Epigenomics Department positions clinicians at the center of this transformation - equipping them with the scientific literacy, clinical frameworks, and board-certified credentials to lead epigenomic medicine in any specialty.
Meet Our Leadership
Director of Epigenomics —
Varun Dwaraka, PhD
Dr. Dwaraka is Head of Bioinformatics at TruDiagnostic, where he leads machine-learning efforts to uncover epigenetic biomarkers associated with molecular ageing, disease, and mortality risk. His work integrates metabolic, proteomic, phenotypic, and DNA methylation data to develop novel age-predictive algorithms.
He holds a PhD in Biology from the University of Kentucky, where he studied the genetic and epigenetic foundations of tissue regeneration in salamanders. His undergraduate training in Molecular, Cellular, and Developmental Biology at UC Santa Cruz focused on bioinformatics.
He has contributed to major research initiatives at institutions including UCSF and the Carnegie Institute of Science, with work featured in Nature Aging and Genome Medicine. He is also a 2023 Foresight Fellow in Biotechnology and Health Expansion and has been featured in Forbes, BBC, Men's Health, Netflix, and HBO.
Faculty Members
Our faculty roster is growing - announcements coming soon.
Faculty position open
Faculty position open
Faculty position open
Faculty position open
Think you're the right fit for a faculty position?
Get Involved →
Shaping the Future
of Precision Medicine
As precision medicine continues to evolve, genomics will play an increasingly central role in redefining how disease is understood, predicted, and treated at the molecular level.
The Genomics Department at ABOPM remains committed to advancing this field through scientific leadership, clinical innovation, and collaborative discovery. Together with our global community of physicians and researchers, we are helping shape the future of next-generation healthcare.
Insights Shaping
Precision Medicine
Explore ABOPM perspectives on genomics, multi-omics, systems thinking, clinical innovation, and the future of physician leadership in precision medicine.
Precision Medicine in Oncology Isn’t the Future - It’s Already Late
Precision medicine in oncology is no longer a distant vision- it is a critical necessity. As cancer care evolves, biomarker-driven diagnostics, genomic sequencing, digital pathology, and AI-powered in... ...more
Precision Oncology
May 17, 2026•4 min read
Pharmacogenomics in Clinical Practice: Prescribing the Right Drug the First Time
Helping clinicians understand how genetic variation influences drug response ...more
Precision Medicine in Action
May 13, 2026•9 min read
Tumor Genomic Profiling: When Should It Be Used in Clinical Practice?
Tumor genomic profiling helps identify actionable mutations to guide targeted therapies and clinical decisions. Understanding when to use it is key to maximizing its impact in precision oncology. ...more
Precision Oncology
May 07, 2026•8 min read
Stay at the Forefront of Precision Medicine
Subscribe to receive ABOPM insights, research updates, and educational resources delivered directly to your inbox.
Advancing education, certification, and leadership to shape a genomics-driven, data-intelligent future of healthcare.
COMPANY
RESOURCES
© 2023-2025 American Board of Precision Medicine, Inc. All Rights Reserved.